Expert Interview
Looking into the recent 12 week results from the phase 2 clinical trial of Barzolvolimab in patients with chronic spontaneous urticaria.
Ticker(s): CLDXInstitution: Self-employed
- Asthma, allergy, and immunology physician in practice for 22 years
- treats patients of all ages and specializes in skin conditions
- prescribed and familiar with Haegarda, Orladeyo, and Takhzyro in patients with HAE
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
